RedHill Biopharma Ltd.
RDHL evidence brief
What we can confirm
- Market Cap:
- $3.7M
What it means
What to watch
Prepared research question
What matters most for RDHL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RDHL
RedHill Biopharma Ltd. (RDHL) is a specialty biopharmaceutical company developing a pipeline of oral drugs, including opaganib for oncology and antiviral indications, and RHB-102 for gastrointestinal side effects, with multiple ongoing clinical and regulatory milestones.
Key risk: Early-stage pipeline
Market Cap
$3.7M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 2 clinical trials for RedHill Biopharma Ltd..
RedHill Biopharma Ltd. (RDHL) is a specialty biopharmaceutical company developing a pipeline of oral drugs, including opaganib for oncology and antiviral indications, and RHB-102 for gastrointestinal side effects, with multiple ongoing clinical and regulatory milestones.
- RedHill is advancing opaganib for Ebola virus disease, with 3,221 cases and 1,407 deaths reported as of July 2026 [news · published 2026-07-28].
- Opaganib received FDA Rare Pediatric Disease designation for neuroblastoma in June 2026, adding to its existing Orphan Drug designation [news · published 2026-06-09].
- RHB-102 (Bekinda®) is being developed via the FDA 505(b)(2) route for GLP-1 therapy-associated GI side effects, targeting a multi-billion-dollar market [news · published 2026-01-05].
- A Phase 2 study of opaganib in combination with darolutamide for metastatic castrate-resistant prostate cancer began recruitment in July 2025 [news · published 2025-07-02].
- Preclinical data presented at AACR 2026 showed opaganib's potential as an add-on therapy in neuroblastoma and triple-negative breast cancer models [news · published 2026-04-22].
What works
- Opaganib has received both FDA Rare Pediatric Disease and Orphan Drug designations for neuroblastoma, which may provide development incentives and market exclusivity [news · published 2026-06-09].
- RHB-102 is pursuing an accelerated FDA 505(b)(2) regulatory pathway for a large, growing market (GLP-1 GI side effects), potentially reducing development time and cost [news · published 2026-01-05].
- The company is actively engaging with the WHO SOLIDARITY CORE trial platform and pharma collaborations for opaganib's Ebola development, indicating external validation and potential for broad use [news · published 2026-06-02].
What to weigh
- Opaganib's clinical pipeline includes multiple early-stage (Phase 2) studies, with no approved products or late-stage pivotal trials yet reported, indicating significant regulatory and commercial risk [news · published 2025-07-02].
- The company's financial results for full-year 2025 were reported in April 2026, but no specific revenue or profitability figures are provided in the available data, suggesting limited financial transparency or ongoing losses [news · published 2026-04-27].
- The Ebola outbreak response is reactive to a rapidly evolving public health emergency, which may create unpredictable development timelines and funding dependencies [news · published 2026-07-28].
From the filings
Quoted directly from source documents.
Opaganib received FDA Rare Pediatric Disease designation for neuroblastoma.
“the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease (RPD) designation to opaganib for treatment of neuroblastoma (NB).”
News · June 9, 2026
RHB-102 is being developed for GLP-1 therapy-associated GI side effects via the 505(b)(2) route.
“development, via the accelerated FDA 505(b)(2) route, as a once-daily oral ondansetron therapy for GLP-1/GIP receptor agonist therapy-associated GI side effects”
News · January 5, 2026
Opaganib combined with venetoclax reduced CLL cells by half in in vivo studies.
“opaganib combined with venetoclax reduces Chronic Lymphocytic Leukemia (CLL) cells by half compared to controls”
News · December 15, 2025
Catalyst timeline
- 2020-08-21 · Phase 2 Start: Opaganib in COVID-19 Pneumonia — A Phase 2/3 study of opaganib for COVID-19 pneumonia began, but no recent updates on this indication are provided in the available data.
- 2018-03-07 · Phase 2 Start: ABC294640 in Cholangiocarcinoma — A Phase 2 study of ABC294640 (opaganib) alone and with hydroxychloroquine for cholangiocarcinoma started, but no recent results are disclosed.
Risks & what to watch (3)›
Key risks
- Early-stage pipeline — All disclosed clinical studies are Phase 2 or earlier; no approved products or Phase 3 data are available, increasing regulatory and commercial risk [news · published 2025-07-02].
- Financial uncertainty — Full-year 2025 financial results were reported but no revenue or profitability figures are provided, suggesting possible ongoing losses or limited disclosure [news · published 2026-04-27].
- Ebola development dependency — Opaganib's Ebola program relies on reactive outbreak dynamics and external collaborations, which may lead to unpredictable timelines and funding [news · published 2026-07-28].
What to watch
- Progress of opaganib in the WHO SOLIDARITY CORE trial platform for Ebola, as discussions are ongoing [news · published 2026-06-02].
- Results from the Phase 2 opaganib/darolutamide combination study in metastatic castrate-resistant prostate cancer, which began recruitment in July 2025 [news · published 2025-07-02].
- Regulatory milestones for RHB-102 under the FDA 505(b)(2) pathway for GLP-1 GI side effects, announced in January 2026 [news · published 2026-01-05].
- Further preclinical or clinical data on opaganib in neuroblastoma and triple-negative breast cancer following AACR 2026 presentations [news · published 2026-04-22].
Sources: Catalysts · Competitor trials · News · Generated October 2, 2026 · How we verify sources →
Run RedHill Biopharma Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available RedHill Biopharma Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
16
Total value held
$386K
| Holder | Shares | Value |
|---|---|---|
| yorkville advisors global, lp | 350,870 | $261K |
| gagnon securities llc | 88,405 | $66K |
| citadel advisors llc | 20,673 | $15K |
| xtx topco ltd | 15,163 | $11K |
| stonex group inc. | 14,481 | $11K |
| two sigma securities, llc | 13,019 | $10K |
| gamma investing llc | 6,684 | $5K |
| rhumbline advisers | 5,116 | $4K |
| federation des caisses desjardins du quebec | 3,388 | $3K |
| ubs group ag | 826 | $615 |
Showing top 10 of 16 institutional holders of RedHill Biopharma Ltd.. Open the full 13F history after sign-in.
Short Interest
as of May 1, 2026- % of float
- 0.1%
- Days to cover
- 0.3
- Shares short
- 7,163
- Daily short volume (Jun 30, 2026)
- 27.1%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RDHL short interestFrequently asked questions
What is the AI investment thesis for RedHill Biopharma Ltd.?
RedHill Biopharma Ltd. (RDHL) is a specialty biopharmaceutical company developing a pipeline of oral drugs, including opaganib for oncology and antiviral indications, and RHB-102 for gastrointestinal side effects, with multiple ongoing clinical and regulatory milestones.
Who is the CEO of RedHill Biopharma Ltd.?
Mr. Dror Ben-Asher is the chief executive officer of RedHill Biopharma Ltd. (RDHL).
Where is RedHill Biopharma Ltd. headquartered?
RedHill Biopharma Ltd. (RDHL) is headquartered in Tel Aviv-Yafo, Israel.
What therapeutic areas does RedHill Biopharma Ltd. focus on?
RedHill Biopharma Ltd. develops therapies across Oncology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.